Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
58.22
+0.34 (+0.58%)
Streaming Delayed Price
Updated: 1:34 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
49
50
Next >
Is Bristol Myers Squibb Stock a Buy?
Today 8:00 EST
Via
The Motley Fool
Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks
Today 4:33 EST
Via
The Motley Fool
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
November 18, 2024
Bristol Myers reports promising preliminary results for its next-gen CAR T therapy CC-97540, showing safety and early efficacy in a Phase 1 study for severe autoimmune diseases.
Via
Benzinga
Not-So-Big Pharma
November 16, 2024
Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration.
Via
Talk Markets
Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 16
November 16, 2024
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Nov. 11-15, 2024.
Via
Talk Markets
How Is The Market Feeling About Bristol-Myers Squibb?
November 04, 2024
Via
Benzinga
Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue
November 15, 2024
Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent value rights holders' payments.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever
November 15, 2024
This fund could be the perfect investment for those wanting financial freedom through endlessly growing dividends.
Via
The Motley Fool
2 Beaten-Down Dividend Stocks to Buy and Hold
November 14, 2024
They're down, but they aren't out, at least not in the eyes of patient investors.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
November 13, 2024
Via
Benzinga
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default
November 13, 2024
Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, impacting future trial plans.
Via
Benzinga
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
November 13, 2024
The company is now pivoting its technology to the cardiovascular space under a partnership with Bristol Myers Squibb.
Via
Investor's Business Daily
3 Stocks Seeing Insider Buys: CNC, PFE, BMY
November 12, 2024
Investors closely monitor insider buys, as they can give hints surrounding the long-term picture. Let’s take a closer look at the transactions for those interested in trading like the insiders.
Via
Talk Markets
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
November 12, 2024
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience strategy and boosting competition for Cobenfy.
Via
Benzinga
This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
November 12, 2024
Via
Benzinga
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
November 12, 2024
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, predicting significant stock outperformance.
Via
Benzinga
What's Going On With Bristol-Myers Squibb Shares Monday?
November 11, 2024
Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie Inc (NYSE:ABBV) announced that its Phase 2 EMPOWER trials did not meet...
Via
Benzinga
Dow, S&P 500 On Track For Milestone Closes
November 11, 2024
Wall Street is extending its post-election rally into a new week.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
November 11, 2024
AbbVie's emraclidine trials for schizophrenia fail, leading to stock decline, but analysts maintain confidence in the company's broader drug pipeline.
Via
Benzinga
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal
November 11, 2024
Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the company.
Via
Benzinga
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
November 11, 2024
AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for next steps.
Via
Benzinga
MARA Holdings, RadNet, Bit Digital, Coinbase And Other Big Stocks Moving Higher On Monday
November 11, 2024
Via
Benzinga
Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails
November 11, 2024
AbbVie stock also tumbled after its experimental schizophrenia treatment failed in two Phase 2 studies.
Via
Investor's Business Daily
MarketBeat Week in Review – 11/4 - 11/8
November 09, 2024
Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts
Via
MarketBeat
Topics
Economy
Government
Exposures
Interest Rates
Political
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
November 08, 2024
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and...
Via
Benzinga
Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast
November 06, 2024
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the consensus of $4.12 billion.
Via
Benzinga
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
November 05, 2024
After strong earnings reports, Merck may be a better choice than Bristol-Meyers in the short term - but both may present a challenge for buy-and-hold investors.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
November 04, 2024
JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 price target amid strong trial results.
Via
Benzinga
Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade
November 01, 2024
On Friday, Bristol Myers Squibb stock earned an upgrade to its Relative Strength (RS) Rating, from 62 to 79.
Via
Investor's Business Daily
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious
November 01, 2024
Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a robust neuropsych pipeline.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
49
50
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.